Laurence H. Beck, Jr uk online pharmacy ., M.D., Ph.D., Ramon G.B. Bonegio, M.D.D., David M. Beck, B.A., David W. Powell, Ph.D., Timothy D. Cummins, M.S., Jon B. Klein, M.D., Ph.D., and David J. Salant, M.D.: M-Type Phospholipase A2 Receptor as Target Antigen in Idiopathic Membranous Nephropathy Idiopathic membranous nephropathy, a common cause of the nephrotic syndrome in adults, can be an organ-specific autoimmune disease. Despite considerable investigation, a focus on antigen offers been elusive. Research of membranous nephropathy in a rat model founded that the subepithelial immune deposits that characterize the condition are created in situ, because of capping and shedding of the prospective antigen, megalin, from the basal surface of podocytes when it forms a complicated with circulating antimegalin antibodies.1-8 Although megalin is not expressed on human being podocytes, we hypothesized a similar procedure, albeit with an unfamiliar antigen, is operative in individual membranous nephropathy.
Statistical Analysis Assuming an event rate for the primary end point of 21 percent with the standard-treatment technique and a 5 percent reduction to follow-up, we approximated that a sample size of 1200 patients would be needed for the study to have 80 percent capacity to show a relative risk reduced amount of 30 percent with the early-PCI strategy, at an alpha level of 0.05. Nevertheless, in November 2007, the steering committee made a decision to stop enrollment by the end of December 2007 owing to slowing enrollment, lack of additional funding, and loss to follow-up that was lower than anticipated. An interim security analysis was performed by the info security and monitoring committee on data from the 1st 536 patients, and the committee identified no safety problems.